比较口服和外用米诺地尔的依从性、副作用和满意度:一项横断面研究。

IF 1.5 4区 医学 Q3 DERMATOLOGY
Sonja Kobayashi, Lucy Rose, Abena Minta, Stephanie Trovato, Brittany Dulmage
{"title":"比较口服和外用米诺地尔的依从性、副作用和满意度:一项横断面研究。","authors":"Sonja Kobayashi, Lucy Rose, Abena Minta, Stephanie Trovato, Brittany Dulmage","doi":"10.36849/JDD.8424","DOIUrl":null,"url":null,"abstract":"<p><p>Hair loss disorders negatively impact quality of life. Topical and oral minoxidil are hair loss therapeutics that require daily use to achieve sustained benefits. Patients on topical minoxidil often report aesthetic and discomfort concerns (eg, greasy hair), which may limit adherence. Oral minoxidil is not FDA-approved for alopecia and carries a higher risk of systemic side effects. Efficacy between the 2 is similar. However, the impact of the route of administration on patient adherence and satisfaction remains unclear. Our study investigates whether topical or oral minoxidil yields greater adherence and satisfaction while comparing side effects. A survey was distributed to patients on minoxidil (n=50, response rate 98.0%) to assess ease of treatment, adherence, satisfaction, and side effects. Patients on oral minoxidil reported greater ease of treatment (P=0.0004) and styling their hair on treatment (P=0.0112). Fewer patients on oral minoxidil stopped treatment due to difficulty of use (0% vs 18.8%, P=0.0076). Oral patients missed less treatment days (x=0.15 vs x=1.2, P=0.0022) and reported greater satisfaction in hair volume (P=0.0098) and change of hair (P=0.0159). Side effects were similar, except for a higher incidence of hypertrichosis among patients on oral minoxidil (48.5% vs 6.25%, P=0.0015). These findings suggest that oral minoxidil is superior to topical in terms of ease of use, adherence, and satisfaction without increasing systemic side effects. By circumventing scalp application, oral minoxidil reduces the treatment burden and avoids the aesthetic and discomfort complaints that limit adherence. When establishing treatment plans, physicians should consider patient experience and its impact on adherence. J Drugs Dermatol. 2025;24(2):131-133. doi:10.36849/JDD.8424.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"131-133"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparing Adherence, Side Effects, and Satisfaction in Oral and Topical Minoxidil: A Cross-Sectional Study.\",\"authors\":\"Sonja Kobayashi, Lucy Rose, Abena Minta, Stephanie Trovato, Brittany Dulmage\",\"doi\":\"10.36849/JDD.8424\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hair loss disorders negatively impact quality of life. Topical and oral minoxidil are hair loss therapeutics that require daily use to achieve sustained benefits. Patients on topical minoxidil often report aesthetic and discomfort concerns (eg, greasy hair), which may limit adherence. Oral minoxidil is not FDA-approved for alopecia and carries a higher risk of systemic side effects. Efficacy between the 2 is similar. However, the impact of the route of administration on patient adherence and satisfaction remains unclear. Our study investigates whether topical or oral minoxidil yields greater adherence and satisfaction while comparing side effects. A survey was distributed to patients on minoxidil (n=50, response rate 98.0%) to assess ease of treatment, adherence, satisfaction, and side effects. Patients on oral minoxidil reported greater ease of treatment (P=0.0004) and styling their hair on treatment (P=0.0112). Fewer patients on oral minoxidil stopped treatment due to difficulty of use (0% vs 18.8%, P=0.0076). Oral patients missed less treatment days (x=0.15 vs x=1.2, P=0.0022) and reported greater satisfaction in hair volume (P=0.0098) and change of hair (P=0.0159). Side effects were similar, except for a higher incidence of hypertrichosis among patients on oral minoxidil (48.5% vs 6.25%, P=0.0015). These findings suggest that oral minoxidil is superior to topical in terms of ease of use, adherence, and satisfaction without increasing systemic side effects. By circumventing scalp application, oral minoxidil reduces the treatment burden and avoids the aesthetic and discomfort complaints that limit adherence. When establishing treatment plans, physicians should consider patient experience and its impact on adherence. J Drugs Dermatol. 2025;24(2):131-133. doi:10.36849/JDD.8424.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"24 2\",\"pages\":\"131-133\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/JDD.8424\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8424","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

脱发障碍会对生活质量产生负面影响。局部和口服米诺地尔是脱发治疗,需要每天使用,以达到持续的好处。局部使用米诺地尔的患者经常报告美观和不适问题(例如,头发油腻),这可能会限制依从性。口服米诺地尔未被fda批准用于治疗脱发,并且有较高的系统性副作用风险。两者的疗效相似。然而,给药途径对患者依从性和满意度的影响仍不清楚。我们的研究调查了外用米诺地尔和口服米诺地尔是否有更好的依从性和满意度,同时比较了副作用。对使用米诺地尔的患者(n=50,有效率98.0%)进行调查,评估治疗难易程度、依从性、满意度和副作用。口服米诺地尔的患者报告治疗更容易(P=0.0004),治疗时发型更容易(P=0.0112)。口服米诺地尔因使用困难而停止治疗的患者较少(0% vs 18.8%, P=0.0076)。口腔患者缺勤天数较少(x=0.15 vs x=1.2, P=0.0022),对发量(P=0.0098)和头发变化(P=0.0159)满意度较高。副作用相似,除了口服米诺地尔患者多毛发生率较高(48.5% vs 6.25%, P=0.0015)。这些发现表明,口服米诺地尔在易用性、依从性和满意度方面优于外用,且不会增加全身副作用。通过绕开头皮应用,口服米诺地尔减少了治疗负担,避免了限制依从性的审美和不适投诉。在制定治疗计划时,医生应考虑患者的经验及其对依从性的影响。皮肤医学杂志,2025;24(2):131-133。doi: 10.36849 / JDD.8424。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparing Adherence, Side Effects, and Satisfaction in Oral and Topical Minoxidil: A Cross-Sectional Study.

Hair loss disorders negatively impact quality of life. Topical and oral minoxidil are hair loss therapeutics that require daily use to achieve sustained benefits. Patients on topical minoxidil often report aesthetic and discomfort concerns (eg, greasy hair), which may limit adherence. Oral minoxidil is not FDA-approved for alopecia and carries a higher risk of systemic side effects. Efficacy between the 2 is similar. However, the impact of the route of administration on patient adherence and satisfaction remains unclear. Our study investigates whether topical or oral minoxidil yields greater adherence and satisfaction while comparing side effects. A survey was distributed to patients on minoxidil (n=50, response rate 98.0%) to assess ease of treatment, adherence, satisfaction, and side effects. Patients on oral minoxidil reported greater ease of treatment (P=0.0004) and styling their hair on treatment (P=0.0112). Fewer patients on oral minoxidil stopped treatment due to difficulty of use (0% vs 18.8%, P=0.0076). Oral patients missed less treatment days (x=0.15 vs x=1.2, P=0.0022) and reported greater satisfaction in hair volume (P=0.0098) and change of hair (P=0.0159). Side effects were similar, except for a higher incidence of hypertrichosis among patients on oral minoxidil (48.5% vs 6.25%, P=0.0015). These findings suggest that oral minoxidil is superior to topical in terms of ease of use, adherence, and satisfaction without increasing systemic side effects. By circumventing scalp application, oral minoxidil reduces the treatment burden and avoids the aesthetic and discomfort complaints that limit adherence. When establishing treatment plans, physicians should consider patient experience and its impact on adherence. J Drugs Dermatol. 2025;24(2):131-133. doi:10.36849/JDD.8424.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信